Evrysdi

Active Ingredient(s): Risdiplam
FDA Approved: * August 7, 2020
Pharm Company: * GENENTECH INC
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Evrysdi Overview

Risdiplam, sold under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy (SMA)[1][2] and the first oral medication approved to treat this disease.[1][2] Risdiplam is a survival of motor neuron 2-directed RNA splicing modifier.[1][3][4] The most common side effects include fever, diarrhoea, rash, ulcers of the mouth area, joint pain (arthralgia) and urinary...

Read more Evrysdi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Risdiplam

Recent Evrysdi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Risdiplam
  • For Solution: 0.75mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Evrysdi: (1 result)

Sorted by National Drug Code
  • 50242-175 Evrysdi .75 mg/ml Oral Powder, for Solution by Genentech Inc.

Other drugs which contain Risdiplam or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 28 September 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA